BACKGROUND AND AIMS: Non-randomised comparative studies of pharmacological agents can be biased because of differences in baseline demographics, medical history and health status of patients prescribed different therapies. Characteristics of patients with type 2 diabetes mellitus (T2DM) taking sitagliptin were compared with patients taking other oral antihyperglycaemic agents (OAHA) in a large US insurance claims database. MATERIALS AND METHODS: Using the United Health Care database, we identified T2DM patients with at least one OAHA prescription, and at least 1 year prior enrollment. Patients were classified into subcohorts including sitagliptin or other OAHA, add-on to monotherapy, and triple or more therapy. Comorbidities 12 months before the first OAHA prescription in study window were based on ICD-9 diagnostic codes and NDC codes for prescriptions. RESULTS: Prevalence of comorbidities was consistently higher for patients with sitagliptin prescriptions across most comorbidities (p < 0.05 for 20 of 30 assessed comorbidities). Overall, baseline differences were apparent (p < 0.0001) for retinopathy (5.7% vs. 3.4%), renal failure (5.1% vs. 2.6%), proteinuria (2.8% vs. 2.0%), hypertension (76.9% vs. 68.2%), congestive heart failure (3.4% vs. 2.6%), myocardial infarction (18.0% vs. 14.4%) and chronic neurological conditions (8.1% vs. 6.6%). Differences were most pronounced for initial monotherapy subcohorts. A higher proportion of sitagliptin users had prescriptions for cardiovascular medication (84.2% vs. 74.9%). CONCLUSION: Sitagliptin users had higher proportions of comorbidities and greater use of prescription medications and physician visits. Researchers should be aware that sitagliptin is prescribed to patients with seemingly worse health status. Ability to analyse observational, non-randomised studies may be limited by substantial differences in patient characteristics between different treatments.
BACKGROUND AND AIMS: Non-randomised comparative studies of pharmacological agents can be biased because of differences in baseline demographics, medical history and health status of patients prescribed different therapies. Characteristics of patients with type 2 diabetes mellitus (T2DM) taking sitagliptin were compared with patients taking other oral antihyperglycaemic agents (OAHA) in a large US insurance claims database. MATERIALS AND METHODS: Using the United Health Care database, we identified T2DM patients with at least one OAHA prescription, and at least 1 year prior enrollment. Patients were classified into subcohorts including sitagliptin or other OAHA, add-on to monotherapy, and triple or more therapy. Comorbidities 12 months before the first OAHA prescription in study window were based on ICD-9 diagnostic codes and NDC codes for prescriptions. RESULTS: Prevalence of comorbidities was consistently higher for patients with sitagliptin prescriptions across most comorbidities (p < 0.05 for 20 of 30 assessed comorbidities). Overall, baseline differences were apparent (p < 0.0001) for retinopathy (5.7% vs. 3.4%), renal failure (5.1% vs. 2.6%), proteinuria (2.8% vs. 2.0%), hypertension (76.9% vs. 68.2%), congestive heart failure (3.4% vs. 2.6%), myocardial infarction (18.0% vs. 14.4%) and chronic neurological conditions (8.1% vs. 6.6%). Differences were most pronounced for initial monotherapy subcohorts. A higher proportion of sitagliptin users had prescriptions for cardiovascular medication (84.2% vs. 74.9%). CONCLUSION:Sitagliptin users had higher proportions of comorbidities and greater use of prescription medications and physician visits. Researchers should be aware that sitagliptin is prescribed to patients with seemingly worse health status. Ability to analyse observational, non-randomised studies may be limited by substantial differences in patient characteristics between different treatments.
Authors: Cynthia J Girman; Mugdha Gokhale; Tzuyung Doug Kou; Kimberly G Brodovicz; Richard Wyss; Til Stürmer Journal: Med Care Date: 2014-03 Impact factor: 2.983
Authors: Samuel S Engel; Elizabeth Round; Gregory T Golm; Keith D Kaufman; Barry J Goldstein Journal: Diabetes Ther Date: 2013-05-23 Impact factor: 2.945
Authors: Kimberly G Brodovicz; Yong Chen; Zhiwen Liu; Mary E Ritchey; Jane Liao; Samuel S Engel Journal: Diabetes Ther Date: 2015-10-05 Impact factor: 2.945
Authors: M Elle Saine; Dena M Carbonari; Craig W Newcomb; Melissa S Nezamzadeh; Kevin Haynes; Jason A Roy; Serena Cardillo; Sean Hennessy; Crystal N Holick; Daina B Esposito; Arlene M Gallagher; Harshvinder Bhullar; Brian L Strom; Vincent Lo Re Journal: BMC Pharmacol Toxicol Date: 2015-04-02 Impact factor: 2.483
Authors: Mikkel Z Ankarfeldt; Brian L Thorsted; Rolf Hh Groenwold; Erpur Adalsteinsson; M Sanni Ali; Olaf H Klungel Journal: Clin Epidemiol Date: 2017-01-18 Impact factor: 4.790